Skip to main content

The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis

Abstract

Background

Transbronchial lung biopsy (TBLB) in the diagnosis of lymphangioleiomyomatosis (LAM) is not a common approach, although TBLB is often performed in diffuse lung diseases. We aimed to examine the diagnostic value and safety of TBLB in LAM patients based on the data collected in our center.

Methods

We reviewed LAM patients registered in our LAM Clinic from December 8, 2006, to December 31, 2019. All patients with definite or probable diagnosis of LAM who had been examined using TBLB were included. All available pathology slides were reviewed by an experienced LAM pathologist. All complications were reviewed by the medical records and confirmed using telephone interviews.

Results

The pathology results of 86 patients (including 74 definite LAM and 12 probable LAM) were available. The positive rate of TBLB in LAM patients was 49/86 (57.0%). The positive rates of SMA, HMB-45, ER, and PR in LAM patients were 97.6%, 93%, 84.6%, and 78.4% respectively. The positive rate of TBLB was 40%, 60% and 60.8% in patients with CT Grade I, Grade II, and Grade III respectively, and the difference was not significant. Patients who had 3–4 or 5–6 biopsied specimens had a higher rate of diagnosis than those with 1–2 biopsied specimens. Four patients (5.6%) reported pneumothorax. No major hemoptysis was reported.

Conclusions

TBLB is a feasible and safe procedure for obtaining a pathological diagnosis of LAM. Taking more than 2 samples during the biopsy procedure increased the rate of diagnosis.

Peer Review reports

Introduction

Lymphangioleiomyomatosis (LAM) is a rare disease that predominantly affects females with clinical features of progressive cystic destruction of the lungs and the accumulation of LAM cells within the lungs and axial lymphatics [1]. Sporadic LAM affects 1 in 400,000 adult females, while it is common in adult females with tuberous sclerosis complex (TSC) [2]. The diagnostic criteria of definite LAM include characteristic or compatible features on high resolution CT of the chest and lung biopsy fitting the pathological criteria for LAM or characteristic high resolution computed tomography (HRCT)features and any of the following: renal angiomyolipoma, thoracic or abdominal chylous effusion, lymphangioleiomyoma or lymph node involvement by LAM, TSC or elevation of vascular endothelial growth factor-D (VEGF-D) in serum [2, 3]. In addition, there are many conditions that can mimic lung cysts and cause cystic lung disease, such as Langerhans cell histiocytosis, lymphoid interstitial pneumonia, and Birt-Hogg-Dubé syndrome [4]. Lung biopsy is important for the diagnosis of LAM. Transbronchial lung biopsy (TBLB) is less invasive than surgical lung biopsy. Current guidelines for LAM recommend TBLB before surgical lung biopsy [3]. However, the experience of this application has seldom been reported since the publication of this recommendation [5, 6]. We aimed to report our experience using TBLB on patients at the LAM Clinic in Peking Union Medical College Hospital (PUMCH), Beijing, China.

Materials and methods

We reviewed LAM patients registered in the LAM center in PUMCH from December 8, 2006, to December 31, 2019, in our database to determine which patients had undergone TBLB. All patients with a definite diagnosis of LAM or probable diagnosis of LAM who had been examined by TBLB were included. The diagnosis criteria of definite LAM were based on ATS/JRS guidelines [3]. The diagnosis criteria of probable LAM were based on ERS guidelines [2]. The following data were collected: [1] diagnosis-related information: history of chylous effusion, HRCT of the chest, CT or magnetic resonance imaging (MRI) or ultrasound of abdomen, and serum VEGF-D; [2] number of samples biopsied during bronchoscopy; [3] pathological results including immunohistochemical examination; and [4] complications during bronchoscopy or within 24 h after the procedure.

Analyses of chest CT scans in these patients were conducted with digital CT images. The thickness of CT slices in most of the patients was high-resolution CT (HRCT), or no more than 5 mm. The severity of abnormalities on CT was graded according to the area of cysts involved: Grade I, cysts less than one-third of lung parenchyma; Grade II, cysts area between one-third and two-thirds of lung parenchyma; and Grade III, two-thirds or more [7].

All pathology slides were reviewed by experienced pathologists in LAM. Pathology slides from other hospitals were re-examined by one of our pathologists if the slides were available. Positive TBLB was defined as lung biopsies positive for HMB-45 or negative for HMB-45 biopsy showing typical LAM cell infiltration in hematoxylin and eosin-stained histological sections.

All complications were reviewed using medical records and confirmed using telephone interviews. Complication of moderate or severe hemoptysis was defined as hemoptysis that was persistent or required treatment. Pneumothorax was defined as a clinical manifestation of pneumothorax and confirmed by X-ray within 24 h of the procedure.

Statistical method

Data were analyzed using SPSS for Windows version 24.0 (IBM Corp., USA) and are reported as the mean (SD). The unpaired t-test was used to compare continuous variables. Categorical variables were compared using Pearson's chi-square test. For all analyses, two-sided tests and a significance level of 0.05 were used.

Results

Patient information

Figure 1 shows the flowchart of the study. In detail, 687 LAM patients registered in PUMCH were reviewed, including 587 definite LAM patients and 100 probable LAM patients. The database recorded 86 of the 687 patients who had a history of TBLB, including 74 definite LAM patients and 12 probable LAM patients. Among 86 patients, 52 underwent TBLB in PUMCH, while 34 underwent TBLB in other hospitals. Six of 34 patients who underwent TBLB not in our hospital had pathological slides reviewed, 4 negative and 2 positive results. One of the 6 patients had the diagnosis revised from negative to positive after pathological slide review.

Fig. 1
figure 1

The flowchart of patient selection

Pathological diagnosis of LAM from TBLB samples

In total, the positive rate of TBLB for LAM diagnosis was 49/86 (57.0%). The positive rate of TBLB performed in PUMCH was 31/52 (59.6%). The positive rate of TBLB performed in other hospitals was 18/34 (52.9%).

For patients with negative TBLB, 20/37 (54%) patients did not have immunohistochemistry testing performed on their samples because there were no typical LAM cell infiltrations in hematoxylin and eosin-stained histological sections. Therefore, we only calculated the immunohistochemistry in the positive TBLB patients. The positive rate of smooth muscle actin (SMA) in patients with positive TBLB was 40/41 (97.6%). The positive rate of HMB-45 in patients with positive TBLB was 40/43 (93%). The positive yields of estrogen receptor (ER) and progesterone receptor (PR) were 33/39 (84.6%) and 29/37 (78.4%), respectively (Fig. 2a; Table 1).

Fig. 2
figure 2

Pathological diagnosis of LAM from TBLB samples. a Positive rate of immunohistochemistry in positive TBLB patients. b Positive rate of TBLB in different CT grades of LAM patients. c Positive rate of TBLB in different numbers of lung biopsy specimens

Table 1 Characteristics comparison between positive TBLB and negative TBLB patients

No difference in diagnostic yield in patients with different severity on CT scans

Seventy-six of 86 LAM patients had available CT scans for analysis. The positive rate of TBLB was 6/15 (40%) in Grade I LAM patients, 6/10 (60%) in Grade II LAM patients, and 31/51 (60.8%) in Grade IIILAM patients. However, there was no significant difference in the positive rate between Grade I, Grade II, and Grade III LAM patients (Grade I vs Grade II, P = 0.428; Grade I vs Grade III, P = 0.154; Grade II vs Grade III, P = 1.000) (Fig. 2b).

Number of biopsy specimens influence the diagnostic yield

Sixty-one of the 86 reports recorded the number of biopsy specimens. Seven patients had 1–2 specimens taken, and the positive rate was only 1/7 (14.3%). Thirty-night patients were 3–4 specimens taken, and the positive rate was 29/46 (63.0%). Seven patients had 5–6 specimens taken, and the positive rate was 7/8 (87.5%). There were significant differences in positive rates between LAM patients with 1–2 specimens and patients with 3–4 specimens (P = 0.044). However, there was no significant difference between patients with 3–4 specimens and patients with 5–6 specimens (P = 0.154) (Fig. 2c).

Complications of TBLB in LAM

Seventy-one of the 86 patients replied to the telephone questionnaire of the complications after the TBLB procedure. Four patients (5.6%) reported pneumothorax, including, three patients had 3 specimens taken, and one patient had 1 specimen taken. Additional biopsies of 5–6 specimens did not increase the rate of PTX. No major hemoptysis was reported. No other complications, such as pulmonary infections, were found.

Discussion

Diagnostic yield was favorable for TBLB in the diagnosis of LAM with varying degrees of lung involvement. The major finding of this work is a 57% positive rate of diagnosis and 5.6% TBLB-related pneumothorax. The positive rate was different between patients who had 1–2 biopsied samples and 3 or more.

Pathology is essential for LAM patients who cannot be definitely diagnosed based on the clinical presentations, VEGF-D, and radiological appearance. In 1991, Pedreira et al. first reported that TBLB was used in the diagnosis of LAM [8]. In 1993, Bonetti et al. recommended that HMB45 should be used to distinguish LAM from other smooth muscle proliferation; the positive rate of HMB-45 in LAM was 92%, and the histological diagnosis of LAM could be made when only a transbronchial biopsy is available [9]. In 2012, Torre and Harari et al. reported that TBLB was performed in seven patients and was diagnostic in six and did not result in complications [10]. Meraj et al. found that TBLB was positive in 6 of 10 patients and had a yield of approximately 60% in LAM, with 52/217 (14%) complications, including pneumothorax (6%), bleeding (4%), chest pain (2%) and pneumonia (2%) [11]. In recent years, some researchers reported that the positive rate of TBLB in patients with LAM was 70–78%, and there were no serious adverse events such as pneumothorax or uncontrollable bleeding due to TBLB [5, 6]. Our results offered similar experience of the value of TBLB in LAM. The positive rate of TBLB in our results was similar to those previously reported [5, 6, 12]. In addition, the complications of TBLB were also similar to previous reports.

Immunostaining with HMB-45 antibody is considered to be the most reliable method for the specific identification of LAM cells [13]. In our study, the positive yield of HMB-45 in the diagnostic biopsies was 93%, which is similar to the previously reported rate of 92% [9]. HMB-45 was not positive in all LAM cells, but it was a valuable marker in LAM [14]. Gao et al.reported that in LAM, the expression of progesterone receptor is frequently higher than that of estrogen receptor [14].However, our pathological reports showed that the positive yields of estrogen receptor (ER) and progesterone receptor (PR) were quite similar (84% and 78%, respectively).

Severity of LAM on CT scans or pulmonary function test may influence the yield of TBLB. Koba et al. found the yield of TBLB was higher in patients with a reduced diffusing capacity [5]. Okamoto et al. reported the severity of LAM on CT scans affected the positive rate of TBLB [6].In our study Grade I LAM patients had a lower positive rate of TBLB than Grade II/III LAM patients although this was not statistically significant. The lack of statistical significance may have resulted from the small sample sizes in each group.

We found that with the increasing number of specimens, the positive rate will improve. The statistically significant increase in yield in going from 1–2 biopsy samples to 3–4 samples. While not statistically significant, there was yet another trend of increase in group of 5–6 samples. Small sample size probably precludes the results to be significant in the comparison of 3–4 samples and 5–6 samples. Increasing the number of specimens did not increase the risk of complications in our reports. However, there is a concern of potential of increased risk of complications when biopsy numbers increase. After balance the potential risk and benefit, we recommend that the number of samples biopsied could be 3–4 during the procedure.

Four patients (5.6%) reported pneumothorax, and no one reported major hemorrhage. Previous reports of TBLB in LAM found 0%-6% pneumothorax and 0%-4% hemorrhage [5, 6, 12].

De Fenoyl et al. reported that pneumothorax occurred in 3.4% of patients with interstitial lung disease who underwent TBLB [15]. The complication of pneumothorax in LAM may be slightly higher than in patients with interstitial lung disease. Evaluation before, during and after the procedure is critical in the early finding of pneumothorax. Large bulli should be avoided during the procedure.

TBLB is effective and safe for patients with LAM; however, some patients cannot be diagnosed with TBLB. Recently, transbronchial cryobiopsy (cryo-TBB) has been introduced as a technique to obtain biopsy samples of lung parenchyma that exceed the size and quality of forceps biopsy samples [16,17,18]. Cryo-TBB yields larger biopsy specimens (43 to 64 mm2) than transbronchial biopsy (5.8 mm2, range 0.58 to 20.88 mm2) [16, 19, 20]. Although crush artifact of TBLB for LAM diagnosis is not a major concern, cryo-TBB may increase the diagnostic yield not only because of increased sample sizes, but also the less injury of tissue structure biopsied. Cryo-TBB in patients with central, peribronchial or diffuse interstitial processes is now used clinically. The major complications of cryo-TBB included pneumothorax (12 to 28%), moderate bleeding (0 to 39%), and rarely death (0.3%) [17, 18, 20]. However, to date there have not been any large case series in LAM patients reporting on the utility of cryo-TBB for diagnosis. Pneumothorax risk is a major concern of cryo-TBB in LAM patients.

One point should be emphasized. Not all patients require pathological evidence for diagnosis. The definite diagnosis of LAM can be made based on characteristic presentations (chylothorax, renal angiomyolipoma, or tuberous sclerosis complex, etc.) or elevation of VEGF-D if characteristic cystic changes in lungs exist. Familiar with clinical features of LAM and tuberous sclerosis complex is essential for appropriate diagnosis. If pathological diagnosis is required, TBLB is recommended first before surgical lung biopsy [3].

There are some limitations to this study. First, it involved a small group of Grade I and Grade II patients; therefore, we do not clearly know whether the severity of CT grades will influence the positive rate of TBLB. Second, how to evaluate the risk of pneumothorax or hemorrhage before the TBLB procedure has not been investigated.

Conclusion

We concluded that TBLB was a favorable and safe diagnostic procedure for LAM. An increasing number of specimens may improve the positive rate. The complication of pneumothorax was low. We support the ATS/JRS guidelines that recommended TBLB should be considered before surgical lung biopsy is considered.

Availability of data and materials

The dataset used and analyzed in current study available from the corresponding author.

Abbreviations

CT:

Computed tomography

ER:

Estrogen receptor

PR:

Progesterone receptor

SMA:

Smooth muscle actin

TBLB:

Transbronchial lung biopsy

References

  1. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27(5):1056–65.

    Google Scholar 

  2. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14–26.

    Google Scholar 

  3. Gupta N. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. Offi Am Thorac Soc. 2017;196(10):1337–48.

    Google Scholar 

  4. Koo HK, Yoo CG. Multiple cystic lung disease. Tubercu Respir Dis. 2013;74(3):97–103.

    Google Scholar 

  5. Koba T, Arai T, Kitaichi M, Kasai T, Hirose M, Tachibana K, Sugimoto C, Akira M, Hayashi S, Inoue Y. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: a report of 24 consecutive patients. Respirology. 2018;23(3):331–8.

    Google Scholar 

  6. Okamoto S, Suzuki K, Hayashi T, Muraki K, Nagaoka T, Nishino K, et al. Transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: the severity of cystic lung destruction assessed by the modified Goddard scoring system as a predictor for establishing the diagnosis. Orphanet J Rare Dis. 2020;15(1):125.

    Google Scholar 

  7. Avila NA, Chen CC, Chu SC, Wu M, Jones EC, Neumann RD, et al. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology. 2000;214(2):441–6.

    Google Scholar 

  8. Díaz Pedreira JA, González-Carreró J, Cameselle Veloso R, Barros Tizón JC, Bandrés Gimeno R. [Pulmonary lymphangioleiomyomatosis. Presentation of a new case]. Anales de medicina interna (Madrid, Spain: 1984). 1991;8 (12):614–6.

  9. Bonetti F, Chiodera PL, Pea M, Martignoni G, Bosi F, Zamboni G, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. Am J Surg Pathol. 1993;17(11):1092–102.

    Google Scholar 

  10. Harari S, Torre O, Cassandro R, Taveira-DaSilva AM, Moss J. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med. 2012;106(9):1286–92.

    Google Scholar 

  11. Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med. 2012;6(4):395–405.

    Google Scholar 

  12. Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Respirology (Carlton, Vic). 2012;6(4):395–405.

    Google Scholar 

  13. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000;67(5):311–29.

    Google Scholar 

  14. Gao L, Yue MM, Davis J, Hyjek E, Schuger L. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch. 2014;464(4):495–503.

    Google Scholar 

  15. de Fenoyl O, Capron F, Lebeau B, Rochemaure J. Transbronchial biopsy without fluoroscopy: a five year experience in outpatients. Thorax. 1989;44(11):956–9.

    Google Scholar 

  16. Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration. 2009;78(2):203–8.

    Google Scholar 

  17. Ravaglia C, Bonifazi M, Wells AU, Tomassetti S, Gurioli C, Piciucchi S, et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration. 2016;91(3):215–27.

    Google Scholar 

  18. Johannson KA, Marcoux VS, Ronksley PE, Ryerson CJ. Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease. A systematic review and metaanalysis. Ann Am Thorac Soc. 2016;13(10):1828–38.

    Google Scholar 

  19. Fruchter O, Fridel L, El Raouf BA, Abdel-Rahman N, Rosengarten D, Kramer MR. Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy. Respirology (Carlton, Vic). 2014;19(5):683–8.

    Google Scholar 

  20. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE. 2014;9(2):e86716.

    Google Scholar 

Download references

Acknowledgements

We thank all the patients for their contribution to this work.

Funding

This work was supported by the National Key Research and Development Program of China (2016YFC0901502), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-2-001), and the National Natural Science Foundation of China (U20A20341).

Author information

Authors and Affiliations

Authors

Contributions

Wenshuai Xu: date collection, data analysis and manuscript writing. Han Cui: date collection, data analysis and manuscript writing. Hongrui Liu: pathology review. Ruie Feng: pathology review. Xinlun Tian: data collection. Yanli Yang: study design, data collection, data analysis. Kai-Feng Xu: study design, data collection, data analysis, manuscript writing. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yanli Yang or Kai-Feng Xu.

Ethics declarations

Ethics approval and consent to participate

All methods of this study were carried out in accordance with relevant guidelines and regulation. The study was part of LAM registry study of Peking Union Medical College Hospital. The protocol of this study was approved by the Ethical Committee of Peking Union Medical College Hospital (S-k1244). All subjects included in this study signed informed consent documents.

Consent for publication

Consent for publication was obtained from all participants.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, W., Cui, H., Liu, H. et al. The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis. BMC Pulm Med 21, 146 (2021). https://doi.org/10.1186/s12890-021-01518-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-021-01518-2

Keywords

  • Lymphangioleiomyomatosis
  • Biopsy
  • Transbronchial lung biopsy
  • Pathology
  • Diagnosis